|
KR20040068613A
(ko)
|
1994-03-25 |
2004-07-31 |
이소테크니카 인코포레이티드 |
중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
|
|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
|
ATE216366T1
(de)
|
1996-08-16 |
2002-05-15 |
Pfizer |
2-aminobenzazepin-derivate und ihre verwendung für die behandlung von immunosuppression
|
|
US20040141983A1
(en)
|
1999-03-15 |
2004-07-22 |
Protein Design Labs, Inc. |
Compositions against cancer antigen LIV-1 and uses thereof
|
|
US20110214206A1
(en)
|
1999-05-06 |
2011-09-01 |
La Rosa Thomas J |
Nucleic acid molecules and other molecules associated with plants
|
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
|
AU2006216669A1
(en)
|
2000-12-08 |
2006-08-31 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
|
GB0118155D0
(en)
|
2001-07-25 |
2001-09-19 |
Lorantis Ltd |
Superantigen
|
|
WO2003094836A2
(en)
|
2001-10-12 |
2003-11-20 |
University Of Iowa Research Foundation |
Methods and products for enhancing immune responses using imidazoquinoline compounds
|
|
US6942972B2
(en)
|
2001-10-24 |
2005-09-13 |
Beckman Coulter, Inc. |
Efficient synthesis of protein-oligonucleotide conjugates
|
|
TW200303759A
(en)
|
2001-11-27 |
2003-09-16 |
Schering Corp |
Methods for treating cancer
|
|
US6953787B2
(en)
|
2002-04-12 |
2005-10-11 |
Arena Pharmaceuticals, Inc. |
5HT2C receptor modulators
|
|
WO2004032829A2
(en)
|
2002-08-15 |
2004-04-22 |
3M Innovative Properties Company |
Immunostimulatory compositions and methods of stimulating an immune response
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
JP2006512391A
(ja)
|
2002-12-30 |
2006-04-13 |
スリーエム イノベイティブ プロパティズ カンパニー |
組み合わせ免疫賦活薬
|
|
PL1610820T5
(pl)
|
2003-04-04 |
2014-01-31 |
Genentech Inc |
Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
|
|
AU2004244962A1
(en)
|
2003-04-10 |
2004-12-16 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds using metal-containing particulate support materials
|
|
US20040265351A1
(en)
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
|
US20050136055A1
(en)
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
WO2005065678A1
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Immunomodulatory combinations
|
|
US7585326B2
(en)
|
2004-08-06 |
2009-09-08 |
Spinalmotion, Inc. |
Methods and apparatus for intervertebral disc prosthesis insertion
|
|
CA2580141C
(en)
|
2004-09-23 |
2013-12-10 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
|
AU2005304771A1
(en)
|
2004-11-09 |
2006-05-18 |
University Of Southern California |
Targeted innate immunity
|
|
DK1907424T3
(en)
|
2005-07-01 |
2015-11-09 |
Squibb & Sons Llc |
HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
|
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
|
|
TW201402124A
(zh)
|
2005-08-19 |
2014-01-16 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
|
|
EP3770174A1
(en)
|
2005-10-11 |
2021-01-27 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
US8951528B2
(en)
|
2006-02-22 |
2015-02-10 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
CA2654317A1
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
|
US20090074711A1
(en)
|
2006-09-07 |
2009-03-19 |
University Of Southhampton |
Human therapies using chimeric agonistic anti-human cd40 antibody
|
|
US7614279B2
(en)
|
2006-10-10 |
2009-11-10 |
Porous Materials, Inc. |
Determination of pore structure characteristics of filtration cartridges as a function of cartridge length
|
|
US8691210B2
(en)
|
2006-10-19 |
2014-04-08 |
David M Spencer |
Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof
|
|
IL199534A
(en)
|
2007-01-05 |
2013-01-31 |
Univ Zuerich |
An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
|
|
HUE033325T2
(en)
|
2007-01-05 |
2017-11-28 |
Univ Zuerich |
Anti-beta-amyloid binder antibodies and their use
|
|
EA019151B1
(ru)
|
2007-02-07 |
2014-01-30 |
Дзе Регентс Оф Дзе Юниверсити Оф Калифорния |
Конъюгаты синтетических агонистов tlr и их применение
|
|
TWI434849B
(zh)
|
2007-06-29 |
2014-04-21 |
Gilead Sciences Inc |
類鐸（Ｔｏｌｌ－ｌｉｋｅ）受體７之調節劑
|
|
RU2010107199A
(ru)
|
2007-07-31 |
2011-09-10 |
Дзе Джонс Хопкинс Юниверсити (Us) |
Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
|
|
ES2445755T3
(es)
|
2007-11-07 |
2014-03-05 |
Celldex Therapeutics, Inc. |
Anticuerpos que se unen a células dendríticas y epiteliales humanas 205 (DEC-205)
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
EP2313111B1
(en)
|
2008-08-01 |
2013-09-04 |
Ventirx Pharmaceuticals, Inc. |
Toll-like receptor agonist formulations and their use
|
|
EA021377B9
(ru)
|
2008-12-09 |
2015-09-30 |
Джилид Сайэнс, Инк. |
Модуляторы толл-подобных рецепторов
|
|
US20110301056A1
(en)
*
|
2008-12-12 |
2011-12-08 |
Oncotherapy Science, Inc. |
Nectin-4 for target genes of cancer therapy and diagnosis
|
|
SG173617A1
(en)
|
2009-02-11 |
2011-09-29 |
Univ California |
Toll-like receptor modulators and treatment of diseases
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US20120121580A1
(en)
|
2009-07-28 |
2012-05-17 |
Merck Sharp & Dohme Corp. |
Methods for producing high concentration lyophilized pharmaceutical formulations
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
WO2011022508A2
(en)
|
2009-08-18 |
2011-02-24 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
|
PL2467380T3
(pl)
|
2009-08-18 |
2017-09-29 |
Ventirx Pharmaceuticals, Inc. |
Podstawione benzoazepiny jako modulatory receptora typu Toll
|
|
SI2491035T1
(sl)
|
2009-10-22 |
2017-10-30 |
Gilead Sciences, Inc. |
Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb
|
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
|
CN107693791B
(zh)
|
2010-02-26 |
2022-06-07 |
诺沃—诺迪斯克有限公司 |
包含稳定抗体的组合物
|
|
CA3188287A1
(en)
|
2010-03-26 |
2011-09-29 |
Memorial Sloan-Kettering Cancer Center |
Antibodies to muc16 and methods of use thereof
|
|
JP5975983B2
(ja)
|
2010-04-16 |
2016-08-23 |
ベリカム ファーマシューティカルズ， インコーポレイテッド |
固形腫瘍を処置するための方法
|
|
CN103153338A
(zh)
|
2010-05-07 |
2013-06-12 |
贝勒研究院 |
树突细胞免疫受体（dcir）介导的人类cd8+t细胞的交叉敏化
|
|
AU2011257219B2
(en)
|
2010-05-28 |
2014-12-04 |
Novo Nordisk A/S |
Stable multi-dose compositions comprising an antibody and a preservative
|
|
AR082686A1
(es)
|
2010-08-13 |
2012-12-26 |
Baylor Res Inst |
Adyuvantes de vacuna que direccionan a los adyuvantes de anticuerpos directamente hacia las celulas presentadoras de antigenos
|
|
MX337873B
(es)
|
2010-09-29 |
2016-03-23 |
Agensys Inc |
Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
|
|
CA2812787A1
(en)
|
2010-10-01 |
2012-04-05 |
Robert Hershberg |
Methods for the treatment of allergic diseases
|
|
CN107970451A
(zh)
|
2010-10-01 |
2018-05-01 |
帆德制药股份有限公司 |
Tlr激动剂和联合治疗的治疗应用
|
|
LT2648752T
(lt)
|
2010-12-06 |
2017-04-10 |
Seattle Genetics, Inc. |
Humanizuoti antikūnai prieš liv-1 ir jų panaudojimas vėžio gydymui
|
|
DE102010062835A1
(de)
|
2010-12-10 |
2012-06-14 |
Codewrights Gmbh |
Verfahren zur Erstellung eines kundenspezifischen Setups für eine Bibliothek von Gerätetreibern
|
|
KR101614997B1
(ko)
|
2011-01-10 |
2016-04-22 |
씨티 아틀란틱 엘티디. |
종양 관련 항원 결합 항체를 포함하는 조합 요법
|
|
PT2663555T
(pt)
|
2011-01-12 |
2017-03-23 |
Array Biopharma Inc |
Benzoazepinas substituídas como moduladores de recetores tipo-toll
|
|
BR112013017943A2
(pt)
|
2011-01-12 |
2018-12-18 |
Array Biopharma Inc |
benzoazepinas substituídas como moduladores receptores do tipo toll
|
|
US20120231023A1
(en)
|
2011-03-08 |
2012-09-13 |
Baylor Research Institute |
Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells
|
|
RS57758B1
(sr)
|
2011-04-08 |
2018-12-31 |
Janssen Sciences Ireland Uc |
Pirimidinski derivati za tretman viralnih infekcija
|
|
CA2831572C
(en)
|
2011-05-02 |
2019-11-26 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
KR102038895B1
(ko)
|
2011-05-18 |
2019-10-31 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염 및 기타 질환 치료용 퀴나졸린 유도체
|
|
EP2747781B1
(en)
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
CA2853114A1
(en)
|
2011-10-24 |
2013-05-02 |
Abbvie Inc. |
Bispecific immunobinders directed against tnf and il-17
|
|
WO2013062083A1
(ja)
|
2011-10-28 |
2013-05-02 |
ファーマロジカルズ・リサーチ プライベート リミテッド |
癌幹細胞特異的分子
|
|
EA037918B1
(ru)
|
2011-12-21 |
2021-06-07 |
Новира Терапьютикс, Инк. |
Противовирусные агенты против гепатита в
|
|
WO2013096835A1
(en)
|
2011-12-23 |
2013-06-27 |
Abbvie Inc. |
Stable protein formulations
|
|
GB201122325D0
(en)
|
2011-12-23 |
2012-02-01 |
Cytoguide As |
Novel formulations
|
|
EA039373B1
(ru)
|
2012-02-08 |
2022-01-19 |
Янссен Сайенсиз Айрлэнд Юси |
Производные пиперидино-пиримидина для лечения вирусных инфекций
|
|
CN104520324A
(zh)
|
2012-02-24 |
2015-04-15 |
施特姆森特Rx股份有限公司 |
Dll3调节剂及其使用方法
|
|
US9556167B2
(en)
|
2012-05-02 |
2017-01-31 |
Yale University |
TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
|
|
MX359257B
(es)
|
2012-05-04 |
2018-09-19 |
Pfizer |
Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna.
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
CA2873646C
(en)
|
2012-05-18 |
2022-04-26 |
Genentech, Inc. |
High-concentration monoclonal antibody formulations
|
|
UY34905A
(es)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
Proteínas de unión a il-1
|
|
PE20150361A1
(es)
|
2012-07-13 |
2015-03-14 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
|
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
CN109232439A
(zh)
|
2012-08-10 |
2019-01-18 |
爱尔兰詹森科学公司 |
用于治疗病毒感染和另外的疾病的烷基嘧啶衍生物
|
|
WO2014052828A1
(en)
|
2012-09-27 |
2014-04-03 |
The Regents Of The University Of California |
Compositions and methods for modulating tlr4
|
|
NZ705589A
(en)
|
2012-10-10 |
2019-05-31 |
Janssen Sciences Ireland Uc |
Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
|
|
US9663474B2
(en)
|
2012-11-16 |
2017-05-30 |
Janssen Sciences Ireland Uc |
Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
|
|
WO2014093936A1
(en)
|
2012-12-13 |
2014-06-19 |
Aduro Biotech, Inc. |
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
|
|
AU2013369982B2
(en)
|
2012-12-28 |
2016-11-17 |
Tva (Abc), Llc |
Targeted conjugates encapsulated in particles and formulations thereof
|
|
US9856319B2
(en)
|
2012-12-28 |
2018-01-02 |
Abbvie Inc. |
Monovalent binding proteins
|
|
WO2014122143A1
(en)
|
2013-02-05 |
2014-08-14 |
Engmab Ag |
Method for the selection of antibodies against bcma
|
|
WO2014124258A2
(en)
*
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
US9598378B2
(en)
|
2013-02-21 |
2017-03-21 |
Janssen Sciences Ireland Uc |
2-aminopyrimidine derivatives for the treatment of viral infections
|
|
WO2014165128A2
(en)
|
2013-03-12 |
2014-10-09 |
Novira Therapeutics, Inc. |
Hepatitis b antiviral agents
|
|
EP2787005A1
(en)
|
2013-04-02 |
2014-10-08 |
Activartis Biotech GmbH |
Targeted cancer immune therapy
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
WO2014172532A2
(en)
|
2013-04-17 |
2014-10-23 |
Lowsky Robert |
Methods for cancer treatment
|
|
US9549944B2
(en)
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
JP6401788B2
(ja)
|
2013-07-30 |
2018-10-10 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
ウイルス感染治療用チエノ［３，２−ｄ］ピリミジン誘導体
|
|
EP3892294A1
(en)
|
2013-08-28 |
2021-10-13 |
AbbVie Stemcentrx LLC |
Site-specific antibody conjugation methods and compositions
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
RU2016129959A
(ru)
|
2013-12-30 |
2018-02-02 |
Эпимаб Биотерепьютикс Инк. |
Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
|
|
CN105899539B
(zh)
|
2014-01-10 |
2021-11-09 |
博笛生物科技有限公司 |
用于免疫疗法的化合物和组合物
|
|
EP3094342A4
(en)
|
2014-01-15 |
2017-12-27 |
Nikolai Khodarev |
Anti-tumor therapy
|
|
WO2015112749A2
(en)
|
2014-01-22 |
2015-07-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
|
|
PT3134402T
(pt)
|
2014-04-22 |
2020-07-02 |
Hoffmann La Roche |
Compostos de 4-amino-imidazoquinolina
|
|
ES2764110T3
(es)
|
2014-04-25 |
2020-06-02 |
Pf Medicament |
Conjugado anticuerpo-fármaco y su utilización para el tratamiento del cáncer
|
|
EP4001311A1
(en)
|
2014-07-09 |
2022-05-25 |
Birdie Biopharmaceuticals Inc. |
Anti-pd-l1 combinations for treating tumors
|
|
CN112546230A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
WO2016011401A1
(en)
|
2014-07-18 |
2016-01-21 |
Kedl Ross M |
Immunostimulatory combinations and use thereof
|
|
JP6744292B2
(ja)
|
2014-07-29 |
2020-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性抗体
|
|
PL3177643T3
(pl)
|
2014-08-04 |
2019-09-30 |
F.Hoffmann-La Roche Ag |
Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
|
|
WO2016036678A1
(en)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
|
KR20170052600A
(ko)
|
2014-09-12 |
2017-05-12 |
제넨테크, 인크. |
시스테인 가공된 항체 및 콘주게이트
|
|
UY36298A
(es)
|
2014-09-16 |
2016-04-29 |
Gilead Science Inc |
Formas sólidas de un modulador del receptor tipo toll
|
|
WO2016064899A1
(en)
|
2014-10-21 |
2016-04-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
|
|
KR20170084202A
(ko)
|
2014-11-14 |
2017-07-19 |
노파르티스 아게 |
항체 약물 접합체
|
|
RS60615B1
(sr)
|
2014-11-20 |
2020-08-31 |
Hoffmann La Roche |
Zajednički laki lanci i postupci upotrebe
|
|
WO2016100302A2
(en)
|
2014-12-16 |
2016-06-23 |
Celgene Corporation |
Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
|
|
PT3233882T
(pt)
|
2014-12-16 |
2020-01-21 |
Kayla Therapeutics |
Dinucleótidos cíclicos fluorados para a indução de citocinas
|
|
WO2016096778A1
(en)
|
2014-12-18 |
2016-06-23 |
F. Hoffmann-La Roche Ag |
Benzazepine sulfonamide compounds
|
|
CN107231804B
(zh)
|
2015-01-14 |
2019-11-26 |
百时美施贵宝公司 |
亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
|
|
GB201501462D0
(en)
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
MA41645A
(fr)
|
2015-03-04 |
2018-01-09 |
Abbvie Stemcentrx Llc |
Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
|
|
MY191185A
(en)
|
2015-03-06 |
2022-06-04 |
Hoffmann La Roche |
Benzazepine dicarboxamide compounds
|
|
US9943416B2
(en)
|
2015-03-10 |
2018-04-17 |
Simplify Medical Pty Limited |
Intervertebral spacer that dynamically promotes bone growth
|
|
WO2017023779A1
(en)
|
2015-07-31 |
2017-02-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
|
US20200079860A1
(en)
|
2015-08-06 |
2020-03-12 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for tumor therapy
|
|
US10738074B2
(en)
|
2015-08-13 |
2020-08-11 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as STING agonists
|
|
EP3349757A1
(en)
|
2015-09-15 |
2018-07-25 |
Gilead Sciences, Inc. |
Modulators of toll-like recptors for the treatment of hiv
|
|
CN108055842B
(zh)
|
2015-09-17 |
2021-06-29 |
豪夫迈·罗氏有限公司 |
亚磺酰基苯基或磺亚胺酰基苯基苯并氮杂䓬
|
|
TWI811892B
(zh)
*
|
2015-09-25 |
2023-08-11 |
美商建南德克公司 |
抗tigit抗體及使用方法
|
|
EP3913000A1
(en)
|
2015-10-02 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
EP3356410B1
(en)
|
2015-10-02 |
2021-10-20 |
F. Hoffmann-La Roche AG |
Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
|
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
DK3380525T3
(da)
|
2015-11-25 |
2024-01-29 |
Immunogen Inc |
Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
WO2017100305A2
(en)
|
2015-12-07 |
2017-06-15 |
Opi Vi - Ip Holdco Llc |
Composition of antibody construct-agonist conjugates and methods of use thereof
|
|
US20170158772A1
(en)
|
2015-12-07 |
2017-06-08 |
Opi Vi - Ip Holdco Llc |
Compositions of antibody construct - agonist conjugates and methods of use thereof
|
|
WO2017117269A1
(en)
|
2015-12-29 |
2017-07-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for dectin-2 stimulation and cancer immunotherapy
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
US10604542B2
(en)
|
2016-01-11 |
2020-03-31 |
Innate Tumor Immunity, Inc. |
Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
|
|
US10723756B2
(en)
|
2016-01-11 |
2020-07-28 |
Innate Tumor Immunity Inc. |
Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
|
|
US20170224837A1
(en)
|
2016-02-10 |
2017-08-10 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
|
US20190048094A1
(en)
|
2016-02-24 |
2019-02-14 |
Oncomed Pharmaceuticals, Inc. |
Redirecting immune responses
|
|
PT3429596T
(pt)
|
2016-03-18 |
2022-11-25 |
Immune Sensor Llc |
Compostos de dinucleotídeos cíclicos e métodos de utilização
|
|
AU2017244108B2
(en)
|
2016-03-29 |
2021-03-18 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
WO2017173403A1
(en)
|
2016-03-31 |
2017-10-05 |
University Of Southern California |
A highly sensitive and specific luciferase based reporter assay for antigen detection
|
|
CA3019396A1
(en)
|
2016-04-13 |
2017-10-19 |
Siluria Technologies, Inc. |
Oxidative coupling of methane for olefin production
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
PT3453707T
(pt)
|
2016-05-06 |
2022-03-15 |
Shanghai De Novo Pharmatech Co Ltd |
Derivado de benzazepina, método de preparação, composição farmacêutica e a sua utilização
|
|
JP7022702B2
(ja)
|
2016-05-23 |
2022-02-18 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
第二級アミド基を有するベンズアゼピンジカルボキサミド化合物
|
|
JP6918838B2
(ja)
|
2016-05-23 |
2021-08-11 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
第三級アミド基を有するベンズアゼピンジカルボキサミド化合物
|
|
WO2017205738A1
(en)
|
2016-05-27 |
2017-11-30 |
Abbvie Biotherapeutics Inc. |
Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
|
|
WO2017216054A1
(en)
|
2016-06-12 |
2017-12-21 |
F. Hoffmann-La Roche Ag |
Dihydropyrimidinyl benzazepine carboxamide compounds
|
|
AU2017291262A1
(en)
|
2016-06-30 |
2019-01-03 |
F. Hoffmann-La Roche Ag |
Improved adoptive T-cell therapy
|
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
EP3484518B1
(en)
|
2016-07-07 |
2024-08-14 |
The Board of Trustees of the Leland Stanford Junior University |
Antibody adjuvant conjugates
|
|
SI3504210T1
(sl)
|
2016-08-29 |
2021-08-31 |
F. Hoffmann-La Roche Ag |
7-substituirane sulfonimidoilpurinonske spojine za zdravljenje virusne okužbe in zaščito pred njo
|
|
CA3034701A1
(en)
|
2016-08-30 |
2018-03-08 |
Board Of Regents, The University Of Texas System |
Production of seleno-biologics in genomically recoded organisms
|
|
US20190345191A1
(en)
|
2016-08-31 |
2019-11-14 |
Innate Tumor Immunity, Inc. |
Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
|
|
US10640499B2
(en)
|
2016-09-02 |
2020-05-05 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
WO2018045144A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
US10537590B2
(en)
|
2016-09-30 |
2020-01-21 |
Boehringer Ingelheim International Gmbh |
Cyclic dinucleotide compounds
|
|
US11001605B2
(en)
|
2016-10-07 |
2021-05-11 |
Biolog Life Science Institute Gmbh & Co. Kg |
Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
|
|
JOP20170188A1
(ar)
|
2016-11-25 |
2019-01-30 |
Janssen Biotech Inc |
ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
|
|
JOP20170192A1
(ar)
|
2016-12-01 |
2019-01-30 |
Takeda Pharmaceuticals Co |
داي نوكليوتيد حلقي
|
|
MX2019006374A
(es)
|
2016-12-02 |
2019-09-11 |
Univ Southern California |
Receptores inmunes sinteticos y metodos de usos de ellos.
|
|
EP3554550A1
(en)
|
2016-12-13 |
2019-10-23 |
Bolt Biotherapeutics, Inc. |
Antibody adjuvant conjugates
|
|
WO2018119118A1
(en)
|
2016-12-20 |
2018-06-28 |
Oncomed Pharmaceuticals, Inc. |
Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof
|
|
SI3570884T1
(sl)
|
2017-01-17 |
2021-02-26 |
Genentech, Inc. |
Subkutane formulacije protiteles HER2
|
|
CA3049791A1
(en)
*
|
2017-01-27 |
2018-08-02 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
EP3573718B1
(en)
|
2017-01-27 |
2022-06-01 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
WO2018144955A1
(en)
|
2017-02-02 |
2018-08-09 |
Silverback Therapeutics, Inc. |
Construct-peptide compositions and methods of use thereof
|
|
US20200055883A1
(en)
|
2017-02-17 |
2020-02-20 |
Eisai R&D Management Co., Ltd. |
Cyclic di-nucleotides derivative for the treatment of cancer
|
|
JP2020508310A
(ja)
|
2017-02-21 |
2020-03-19 |
ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System |
インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド
|
|
US11274160B2
(en)
|
2017-03-02 |
2022-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to Nectin-4 and uses thereof
|
|
WO2018170179A1
(en)
|
2017-03-15 |
2018-09-20 |
Silverback Therapeutics, Inc. |
Benzazepine compounds, conjugates, and uses thereof
|
|
ES2939384T3
(es)
|
2017-04-14 |
2023-04-21 |
Bolt Biotherapeutics Inc |
Método de síntesis de inmunoconjugados
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
JP7168590B2
(ja)
|
2017-06-05 |
2022-11-09 |
アジェンシス インコーポレーテッド |
ネクチン４結合性タンパク質及びその使用方法
|
|
WO2018227023A1
(en)
|
2017-06-07 |
2018-12-13 |
Silverback Therapeutics, Inc. |
Antibody construct conjugates
|
|
CN110891605A
(zh)
|
2017-06-07 |
2020-03-17 |
希沃尔拜克治疗公司 |
免疫调节化合物的抗体缀合物及其用途
|
|
MA49403A
(fr)
|
2017-06-12 |
2021-03-24 |
Obsidian Therapeutics Inc |
Compositions de pde5 et méthodes d'immunothérapie
|
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
|
MX2020004185A
(es)
|
2017-09-27 |
2021-01-08 |
Univ Southern California |
Nuevas plataformas para coestimulacion, nuevos diseños car y otras mejoras para terapia celular adoptiva.
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
JP2021503005A
(ja)
|
2017-11-14 |
2021-02-04 |
ダイナバックス テクノロジーズ コーポレイション |
Ｔｌｒ７／８アゴニスト化合物の切断可能なコンジュゲート、その調製方法および使用
|
|
CA3084667A1
(en)
|
2017-12-15 |
2019-06-20 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
|
JP7506981B2
(ja)
|
2017-12-21 |
2024-06-27 |
住友ファーマ株式会社 |
Ｔｌｒ７アゴニストを含む併用薬
|
|
US12077583B2
(en)
|
2018-05-09 |
2024-09-03 |
Nectin Therapeutics Ltd. |
Antibodies specific to human NECTIN4
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
CA3110510A1
(en)
|
2018-08-29 |
2020-03-05 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting egfr
|
|
CA3111580A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Antibody conjugates of toll-like receptor agonists
|
|
WO2020056198A2
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Substituted benzazepine compounds, conjugates, and uses thereof
|
|
CA3111784A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Methods and compositions for the treatment of disease with immune stimulatory conjugates
|
|
WO2020056194A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Benzazepine compounds, conjugates, and uses thereof
|
|
US20220135678A1
(en)
|
2019-01-18 |
2022-05-05 |
University Of Southern California |
Methods and compositions to improve the safety and efficacy of cellular therapies
|
|
CN113993549A
(zh)
|
2019-03-15 |
2022-01-28 |
博尔特生物治疗药物有限公司 |
靶向her2的免疫缀合物
|
|
WO2020190734A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting pd-l1
|
|
WO2020190731A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
|
WO2020190762A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Macromolecule-supported tlr agonists
|
|
WO2020190760A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting cea
|
|
CA3142887A1
(en)
|
2019-06-13 |
2020-12-17 |
Bolt Biotherapeutics, Inc. |
Aminobenzazepine compounds, immunoconjugates, and uses thereof
|
|
WO2020252254A1
(en)
|
2019-06-13 |
2020-12-17 |
Bolt Biotherapeutics, Inc. |
Macromolecule-supported aminobenzazepine compounds
|
|
WO2020257407A1
(en)
|
2019-06-19 |
2020-12-24 |
Silverback Therapeutics, Inc. |
Anti-mesothelin antibodies and immunoconjugates thereof
|
|
EP3996730A2
(en)
|
2019-07-09 |
2022-05-18 |
The Johns Hopkins University |
Molecules, compositions and methods for treatment of cancer
|
|
CA3146661A1
(en)
|
2019-07-16 |
2021-01-21 |
Silverback Therapeutics, Inc. |
Alk5 inhibitors, conjugates, and uses thereof
|
|
WO2021030665A1
(en)
|
2019-08-15 |
2021-02-18 |
Silverback Therapeutics, Inc. |
Formulations of benzazepine conjugates and uses thereof
|
|
CA3151322A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|